Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial.

DiabetologiaJun 6, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Evelyn B Parr, Rasha Charrouf, Amy T Hutchison et al.

✦ AI-curated · Sources linked

In 30 seconds

This non-inferiority randomized clinical trial evaluated the effects of time-restricted eating (TRE) compared to individualized dietetic guidance (IDG) on HbA1c levels in 247 adults at risk of type 2 diabetes over 4 months. TRE was found to be non-inferior to IDG for HbA1c change (mean difference: -0.22 mmol/mol), but not superior. At 12 months, non-inferiority could not be concluded.

Key findings

  • At 4 months, TRE showed a mean HbA1c change of -0.22 mmol/mol compared to IDG.
  • At 12 months, the upper bound of the HbA1c difference exceeded the non-inferiority margin.
  • Both interventions resulted in small and not clinically meaningful changes in HbA1c.
  • Adverse events were minor and similar between TRE and IDG.

Why it matters

Understanding the effectiveness of TRE as an alternative to traditional dietetic guidance is crucial for managing patients at risk of type 2 diabetes, especially when access to dietitians is limited.

Source

Published in Diabetologia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.